Page last updated: 2024-10-15

deoxyinosine

Cross-References

ID SourceID
PubMed CID135398593
CHEMBL ID1229971
CHEBI ID28997
SCHEMBL ID24307
SCHEMBL ID12541694
MeSH IDM0059192

Synonyms (68)

Synonym
CHEMBL1229971
9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-9h-purin-6-ol
9-(2-deoxy-beta-d-erythro-pentofuranosyl)-9h-purin-6-ol
CHEBI:28997 ,
inosine, 2'-deoxy-
c10h12n4o4
890-38-0
DEOXYINOSINE ,
2'-deoxyinosine ,
C05512
2'-deoxyinosine, >=98%
DB02380
NCGC00161962-01
2ND ,
1871BC26-669C-4B3A-8203-11AAECAA0F70
9-(2-deoxy-beta-d-ribofuranosyl)hypoxanthine
D3584
9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one
9-[(2r,4s,5r)-5-(hydroxymethyl)-4-oxidanyl-oxolan-2-yl]-3h-purin-6-one
9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-oxolanyl]-3h-purin-6-one
A843052
9-(2-deoxy-beta-delta-erythro-pentofuranosyl)-1,9-dihydro-6h-purin-6-one
9-(2-deoxy-beta-delta-erythro-pentofuranosyl)-hypoxanthine
9-(2-deoxy-beta-d-erythro-pentofuranosyl)-hypoxanthine
delta-ino
d-ino
9-(2-deoxy-b-d-erythro-pentofuranosyl)-1,9-dihydro-6h-purin-6-one
9-(2-deoxy-b-d-erythro-pentofuranosyl)-hypoxanthine
2deoxy-inosine
BMSE000942
9-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9h-purin-6-ol
S3757
hn0rq6sbwq ,
unii-hn0rq6sbwq
einecs 212-964-1
AKOS015900773
HG1184
gtpl5110
9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3h-purin-6-one
6h-purin-6-one, 9-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-1,9-dihydro-
2'-deoxyinosine [who-ip]
2'-deoxyinosine [usp impurity]
hypoxanthine, 9-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-
didanosine impurity c
9-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-1,9-dihydro-6h-purin-6-one [who-ip]
9-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-1,9-dihydro-6h-purin-6-one
didanosine impurity c [ep impurity]
bdbm50421823
9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-9h-purin-6-ol
SCHEMBL24307
VGONTNSXDCQUGY-RRKCRQDMSA-N
2'-desoxyinosin
AKOS024282324
SCHEMBL12541694
mfcd00005762
AKOS026750182
2'-deoxyinosine, 99%
AC-8207
AS-73354
2-deoxy-inosine
CS-W009354
HY-W008638
9-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-purin-6(9h)-one
Q27071895
CCG-266978
9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-purin-6-one
?2'-deoxyinosine(di)
DTXSID101346428

Research Excerpts

Overview

Deoxyinosine (dI) is a highly mutagenic lesion that preferentially pairs with deoxycytidine during replication, which may induce A to G transition and ultimately contribute to carcinogenesis. It is a potent inhibitor for growth of the promastigote form of Leishmania tropica.

ExcerptReference
"Deoxyinosine (dI) is a highly mutagenic lesion that preferentially pairs with deoxycytidine during replication, which may induce A to G transition and ultimately contribute to carcinogenesis. "( Development of an Endonuclease V-Assisted Analytical Method for Sequencing Analysis of Deoxyinosine in DNA.
Chen, D; Dai, X; You, C; Zhao, Y; Zheng, X, 2022
)
"3'-Deoxyinosine is a potent inhibitor for growth of the promastigote form of Leishmania tropica. "( 3'-Deoxyinosine as an anti-leishmanial agent: the metabolism and cytotoxic effects of 3'-deoxyinosine in Leishmania tropica promastigotes.
Hiraoka, O; Wataya, Y, 1984
)

Compound-Compound Interactions

ExcerptReference
"We investigated the effects of 2'-deoxyinosine (d-Ino), a modulator yielding thymidine phosphorylase activity, on cellular pharmacology of 5-fluorouracil (FUra) in various human colorectal cell lines and its antitumoral activity when combined with FUra in human xenografts."( Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.
Aubert, C; Catalin, J; Ciccolini, J; Cuq, P; Evrard, A; Formento, P; Milano, G; Peillard, L; Pelegrin, A, 2000
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
purine 2'-deoxyribonucleosideA 2'-deoxyribonucleoside that has a purine moiety as the nucleobase (the R group in the illustration).
purines 2'-deoxy-D-ribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
Deoxy-inosine + Orthophosphate = 2-Deoxy-D-ribose 1-phosphate + Hypoxanthine ( Purine nucleotides and Nucleosides metabolism )14
Purine metabolism1336
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
salvage pathways of adenine, hypoxanthine, and their nucleosides023
Purine metabolism and related disorders2353

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency7.18380.000811.382244.6684AID686978; AID686979
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency8.91250.354828.065989.1251AID504847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine deaminase Bos taurus (cattle)Ki150.00000.00000.48937.0000AID33651
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
adenosine catabolic processAdenosine deaminase Bos taurus (cattle)
cell adhesionAdenosine deaminase Bos taurus (cattle)
nucleotide metabolic processAdenosine deaminase Bos taurus (cattle)
purine ribonucleoside monophosphate biosynthetic processAdenosine deaminase Bos taurus (cattle)
inosine biosynthetic processAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
adenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
protein bindingAdenosine deaminase Bos taurus (cattle)
zinc ion bindingAdenosine deaminase Bos taurus (cattle)
2'-deoxyadenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
lysosomeAdenosine deaminase Bos taurus (cattle)
cytoplasmic vesicle lumenAdenosine deaminase Bos taurus (cattle)
anchoring junctionAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID33651Ability to inhibit adenosine deaminase1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Synthesis, structure, and biological activity of certain 2-deoxy-beta-D-ribo-hexopyranosyl nucleosides and nucleotides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (112)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (21.43)18.7374
1990's29 (25.89)18.2507
2000's36 (32.14)29.6817
2010's18 (16.07)24.3611
2020's5 (4.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other113 (99.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]